Erica Friedman • June 17, 2025
Alnylam Announces FDA Approval of AMVUTTRA® (vutrisiran) for Adults with ATTR Amyloidosis with Cardiomyopathy (ATTR-CM)

AMVUTTRA® (vutrisiran) has been approved by the U.S. Food and Drug Administration (FDA) to treat ATTR-CM in adults. 

AMVUTTRA is an RNAi therapeutic that works upstream to deliver rapid knockdown of TTR, addressing the disease at its source, with only four convenient subcutaneous doses per year. By rapidly knocking down TTR production, AMVUTTRA substantially decreases deposition of TTR fibrils, which form amyloid and cause irreversible cardiovascular damage and premature death in patients with ATTR-CM.


Alnylam is incredibly grateful to the patients who participated in clinical trials to advance the treatment of ATTR-CM, including those who participated in the HELIOS-B study. We’re also thankful to their families who supported them and the incredible efforts of the advocacy community, investigators and study staff for their important contributions.

 

To ensure patients who need AMVUTTRA have access to it, Alnylam offers multiple patient support services and resources through Alnylam Assist®, designed to help patients and their families navigate the treatment journey. As part of Alnylam Assist®, Alnylam offers low or no cost programs for eligible patients and most patients treated with AMVUTTRA pay $0 out of pocket. If you would like to learn more about how Alnylam can support patients, you can visit AlnylamAssist.com/AMVUTTRA.


For more information, please see the full Anylam press release.

For a plain language summary of the full publication, Please visit:  Treatment with vutrisiran in people withtransthyretin amyloidosis with cardiomyopathy:a plain language summary


HCMA Blog

By Lisa Salberg October 10, 2025
The Price of Love: A Tribute to Esther
By Sabrina Cuddy August 1, 2025
On a background of pink
By Julie Russo July 31, 2025
Sixty years ago, Medicaid and Medicare were established when President Lyndon B. Johnson signed the Social Security Amendments into law. The programs were a larger part of Johnson's "War on Poverty" agenda to combat inequality. Sixty years later, Medicaid and Medicare are under attack in ways that we could never have imagined. With the passage of the One Big Beautiful Bill Act (OBBBA), $1 trillion was cut from Medicaid and Medicare―the largest health care cut in U.S. history. As a result of the budget package, more than 15 million people will lose health insurance, hundreds of rural hospitals will close, and approximately 51,000 people will die preventable deaths each year. Congress voted for this harm, and Congress can fix it. We need them to invest in Medicaid and Medicare in order to undo this damage. Click here to send a message to Congress telling them to invest in these critical programs, not cut them. OBBBA is the exact opposite of the "War on Poverty." The bill was passed with brutal cuts to health care to fund more tax handouts for the very wealthy. It took from the poor to give to the rich. The unpopularity of these cuts cannot be overstated. Eighty-three percent of the American public, including three in four Republicans, has a favorable view of Medicaid. Congress must hear from us loud and clear: reverse course, undo the harm to Medicaid and Medicare, and protect health care for more than 71 million people. Join us in sending the message to Congress to invest in these critical programs, don't cut them. 1 The Truth About the One Big Beautiful Bill Act’s Cuts to Medicaid and Medicare 2 Research Memo: Projected Mortality Impacts of the Budget Reconciliation Bill 3 Medicaid keeps getting more popular as Republicans aim to cut it by $800 billion
More Posts